NRD
TMCI icon

Nebula Research & Development’s Treace Medical Concepts TMCI Stock Holding History

Nebula Research & Development’s Portfolio TMCI Stock Details TMCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,126
Closed -$85K – 1153
2025
Q1 		$85K Buy
+10,126
New +$91K 0.01% 914

Other funds holding TMCI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nebula Research & Development's TMCI Position: Q2 2025 in Review

Nebula Research & Development sold out of Treace Medical Concepts (TMCI) in Q2 2025, closing a stake of 10,126 shares — an estimated $85K sold.

Nebula Research & Development first reported a position in TMCI in Q1 2025 and held it in 1 quarter. The position peaked at $85K in Q1 2025. 125 funds tracked by Wall St. Rank hold TMCI as of Q2 2025.

  • Nebula Research & Development reported no remaining Treace Medical Concepts position as of Q2 2025 after selling out during the quarter.
  • Nebula Research & Development sold 10,126 Treace Medical Concepts shares in Q2 2025, an estimated $85K.
  • Nebula Research & Development first reported a position in Treace Medical Concepts in Q1 2025 and held it in 1 quarter.
  • Nebula Research & Development's Treace Medical Concepts position peaked at $85K in Q1 2025.
  • 125 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q2 2025.

Based on Nebula Research & Development's 13F filing for Q2 2025, filed 14 Aug 2025.